For decades, doctors prescribed it to control blood sugar.
Now, some scientists think it may be quietly nudging ageing itself.
The same unassuming pill millions of people take for type 2 diabetes is drawing attention for a far more ambitious reason: its potential to delay the biological wear and tear that comes with getting older. Early data hint that this old drug, metformin, could slightly bend the curve of ageing by acting on core processes that drive many age-related diseases.
Ageing becomes a medical target, not just bad luck
Medicine used to tackle illness one diagnosis at a time: heart disease here, cancer there, dementia later. That approach worked when lives were shorter. As populations live into their 80s and 90s, many people now develop several chronic diseases at once, stretching health systems and families.
Researchers are shifting focus. Instead of treating each disease in isolation, they are asking whether we can slow the underlying biological ageing that fuels them all. Ageing is no longer seen as a passive slide into decline, but as a set of processes that can, at least in part, be tweaked.
Studies in cells, animals and humans point to recurring culprits:
- chronic low-grade inflammation that never quite switches off
- metabolic disruptions, including high blood sugar and insulin resistance
- accumulated damage to DNA, proteins and cell structures
- faulty mitochondria, the tiny power plants inside cells
Instead of stretching life at any cost, the aim is to extend the years spent mobile, mentally sharp and largely disease-free.
Because many major diseases of old age share these pathways, nudging them in a healthier direction might delay several conditions at once. Reviews in journals such as Ageing Research Reviews have labelled such interventions “geroprotectors” – treatments that could protect against the harmful aspects of ageing itself.
The unlikely anti-ageing candidate in the diabetes aisle
Metformin has been around since the 1950s and is usually prescribed as a first-line treatment for type 2 diabetes. Its job is straightforward: help the body respond better to insulin and lower blood sugar levels.
Yet large epidemiological studies kept revealing something curious. People with diabetes on metformin often did as well as – and in some datasets, slightly better than – non-diabetic people in terms of lifespan and risk of some diseases. That raised an eyebrow in ageing labs across the world.
How metformin tinkers with cellular ageing
On a molecular level, metformin influences energy use inside cells. It appears to send a “low fuel” signal, triggering responses that overlap with those seen in calorie restriction, a well-studied way to lengthen healthy life in animals.
➡️ UK, UN and EU deplore ‘monumental injustice’ of Jimmy Lai’s 20-year jail sentence | Jimmy Lai
➡️ Should you choose winter tires or all-season tires? We answer once and for all
➡️ Switzerland has quietly built a massive underground network by tunneling for 30 years
Key effects include:
- lowering insulin and growth factor levels, which are linked to cancer risk and faster ageing
- reducing the production of harmful reactive oxygen species, which can damage cells
- activating an enzyme called AMPK, a master regulator of cellular metabolism
- boosting autophagy, the cell’s internal recycling process
- dampening cellular senescence, where old cells stop dividing but keep releasing inflammatory signals
By acting on central metabolic switches like AMPK, metformin may nudge cells into a more “maintenance and repair” mode instead of constant growth.
Reviews in journals such as Cell Metabolism suggest that metformin touches several of the recognised “hallmarks of ageing” at once. That does not mean it freezes time, but it may slightly slow the rate at which damage accumulates.
Hints from real people: a lower risk of earlier death
Animal and lab findings often fail to translate into humans, so researchers are cautious. Still, some long-term observational data are raising interest.
One analysis drew on the Women’s Health Initiative, a huge US study that has followed hundreds of thousands of women for decades. Among women over 60 with type 2 diabetes, those treated with metformin had about a 30% lower chance of dying before age 90 compared with peers using other diabetes drugs.
In this cohort, metformin users were more likely to reach exceptional ages than women with similar health profiles on different treatments.
The study does not prove that metformin itself caused the difference. Women on the drug might have had better access to care, different lifestyles or milder diabetes. Still, when such trends appear repeatedly in different datasets, they become hard to ignore.
TAME: the trial that treats ageing like a disease
To move from hints to harder evidence, scientists are preparing a landmark clinical trial called TAME, short for Targeting Aging with Metformin. The idea is simple but radical: test whether one inexpensive drug can delay the onset of several age-related diseases at once.
Instead of focusing on a single outcome, TAME will track a composite of events in older adults, such as:
- heart attacks and strokes
- cancers
- cognitive decline and dementia
- loss of physical independence
If metformin users develop these problems later than those on placebo, that would support the concept that ageing processes themselves are being nudged.
TAME does not aim to create ageless humans; it aims to see whether one cheap, familiar pill can keep people healthier for longer into old age.
Who should and should not consider metformin right now
The possibility of a “longevity pill” attracts huge attention, but the current medical advice stays conservative. Metformin is approved for treating type 2 diabetes and, in some cases, prediabetes or polycystic ovary syndrome. It is not officially recommended purely for healthy ageing.
Doctors usually prescribe or avoid it based on factors such as:
| Situation | How metformin is usually viewed |
|---|---|
| Type 2 diabetes, normal kidney function | Often first-line treatment |
| Prediabetes and high risk of diabetes | Sometimes used, especially with lifestyle changes |
| Healthy person, no blood sugar issues | Not routinely prescribed; evidence still emerging |
| Significantly reduced kidney function | Used with caution or avoided |
Common side effects include digestive discomfort, such as nausea and diarrhoea, especially at the start. Rarely, very high levels of the drug in people with severe kidney problems can trigger lactic acidosis, a dangerous condition. That is one reason metformin is not a casual supplement.
Why targeting ageing could change healthcare costs
If a single, low-cost drug could moderately delay several chronic diseases, the impact would stretch beyond individuals. Health systems face rising costs from prolonged disability, long-term care and advanced treatments for late-stage disease.
Delaying the onset of multiple conditions by just a few years could reduce years of frailty, cut hospital admissions and shorten periods of heavy caregiving. Public health economists are already modelling scenarios where even modest effects on ageing biology translate into substantial savings and improved quality of life at a population level.
Key concepts behind the hype
Two scientific ideas often mentioned in this debate are worth unpacking:
- Biological age vs chronological age
Chronological age is the number of years you have lived. Biological age reflects how “worn” your tissues and organs appear, based on markers like DNA methylation patterns, inflammation levels and fitness. A 70-year-old can have the biological profile of a typical 60-year-old – or of an 80-year-old. - Hallmarks of ageing
Researchers have listed recurring processes that seem to drive ageing, including genomic instability, loss of proteostasis (protein balance), mitochondrial dysfunction, stem cell exhaustion and altered intercellular communication. Drugs like metformin are judged by how many of these levers they can adjust.
What this could mean for everyday choices
Metformin, even if it proves useful against ageing, will never replace lifestyle. The same biological systems it touches are strongly shaped by daily habits. Regular exercise, balanced diets, good sleep and not smoking all influence insulin sensitivity, inflammation and cellular repair.
Some researchers even worry that using metformin in highly active people might blunt some benefits of exercise, because both act on similar pathways like AMPK. A few small studies in older adults have hinted that metformin could slightly reduce gains in muscle strength from training, although findings remain mixed and the effects, if real, appear modest.
For now, the realistic scenario looks less like a magic youth pill and more like a potential future tool used alongside lifestyle changes. If trials such as TAME deliver positive results, doctors might one day prescribe metformin to certain older adults not just to manage sugar levels, but to gently slow the cascade of age-related diseases – essentially buying a little more healthy time.